Kisunla 350 mg concentrate for solution for infusion
*Company:
Eli Lilly and Company (Ireland) LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
File name
APPROVED_IE_Kisunla_aRMM- Patient Card_Jun2026_CMAT-21619.pdf
Reasons for updating
- Add New Doc
File name
APPROVED_IE_Kisunla_aRMM- HCP Education Guide_29July2026_CMAT-21623 1.pdf
Reasons for updating
- Add New Doc
Updated on 18 March 2026
File name
Kisunla_PIL_Mar26_IE.pdf
Reasons for updating
- New PIL for new product
Updated on 18 March 2026
File name
Kisunla_SmPC_Mar26_IE.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Eli Lilly and Company (Ireland) Limited
 Limited.webp)
Address:
Lilly House, Basing View, Basingstoke, Hampshire, RG21 4FA, United KingdomMedical Information E-mail:
ukmedinfo@lilly.comTelephone:
+353 1 661 4377Website:
https://www.lilly.ie